Recurrent Respiratory Papillomatosis and Extraesophageal Reflux
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Recurrent Respiratory Papillomatosis
- Sponsor
- University Hospital Ostrava
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Occurrence of EER (percentage)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).
Detailed Description
Recurrent respiratory papillomatosis (RRP) is a chronic viral disease, which affects children and adults as well. It is characterised by grow of squamous cell tumours on mucosa of aerodigestive tract, with predilection for the larynx. The disease is caused by the human papillomavirus (HPV). However, in contrast to the low incidence of RRP, HPV prevalence is common. It is indicated that other factors may contribute to the pathogenesis of RRP. One such factor might be extraesophageal reflux (EER). We investigated whether patients with RRP suffer more often from EER.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age 1-75 years
- •cooperating patients with laryngeal papillomatosis
- •patients tolerating impedance probe
- •signed informed consent, consent with the examinations
- •control group of patients with a cyst or vocal cord polyp (reflux finding score 0-2) and/or patients indicated to augmentation, medialization or lateralization of the vocal cords
Exclusion Criteria
- •patients non-tolerating impedance catheter
- •patients who do not understand Czech language
- •patients who do not proclaim consent with enrolment into the study
- •patients who do not proclaim consent with the planned examinations
- •patients after surgical treatment of tumour of the swallowing or respiratory tract
Outcomes
Primary Outcomes
Occurrence of EER (percentage)
Time Frame: 36 months
The occurrence of extra oesophageal reflux will be assessed in both study groups.
Secondary Outcomes
- Presence of pepsin(36 months)